At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
RVMD Revolution Medicines, Inc.
Pre-Mkt 05-13 06:12:56 EDT
145.72
+1.57
+1.09%
盘前147.01
+1.29+0.89%
04:31 EDT
High146.11Low141.18Vol1.42M
Open144.00D1 Closing144.15Amplitude3.42%
Mkt Cap30.98BTradable Cap27.54BTotal Shares212.59M
T/O205.07MT/O Rate0.75%Tradable Shares189.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

LifeSci Capital Sticks to Their Buy Rating for Revolution Medicines (RVMD)
TIPRANKS  ·  05-10
LifeSci Capital Sticks to Their Buy Rating for Revolution Medicines (RVMD)
Alphabet Reports Stake In PayPay And CME Group, Dissolves In Dexcom
Reuters  ·  05-08
Alphabet Reports Stake In PayPay And CME Group, Dissolves In Dexcom
Revolution Medicines Warrants: Balancing Dilution Risk and Potential Worthlessness Ahead of 2026 Expiry
TIPRANKS  ·  05-08
Revolution Medicines Warrants: Balancing Dilution Risk and Potential Worthlessness Ahead of 2026 Expiry
Revolution Medicines price target raised to $185 from $170 at BofA
TIPRANKS  ·  05-08
Revolution Medicines price target raised to $185 from $170 at BofA
Evercore ISI Sticks to Their Buy Rating for Revolution Medicines (RVMD)
TIPRANKS  ·  05-07
Evercore ISI Sticks to Their Buy Rating for Revolution Medicines (RVMD)
Revolution Medicines: Buy Rating Backed by Strong Daraxon Launch Signals and Pancreatic Cancer Upside Optionality
TIPRANKS  ·  05-07
Revolution Medicines: Buy Rating Backed by Strong Daraxon Launch Signals and Pancreatic Cancer Upside Optionality
RBC Capital Adjusts Revolution Medicines Price Target to $165 From $162, Maintains Outperform Speculative Risk Rating
MT Newswires Live  ·  05-07
RBC Capital Adjusts Revolution Medicines Price Target to $165 From $162, Maintains Outperform Speculative Risk Rating
Revolution Medicines Inc : JP Morgan Raises Target Price to $200 From $175
THOMSON REUTERS  ·  05-07
Revolution Medicines Inc : JP Morgan Raises Target Price to $200 From $175
Wedbush Raises Price Target on Revolution Medicines to $165 From $147, Keeps Outperform Rating
MT Newswires Live  ·  05-07
Wedbush Raises Price Target on Revolution Medicines to $165 From $147, Keeps Outperform Rating
Revolution Medicines Is Maintained at Buy by Needham
Dow Jones  ·  05-07
Revolution Medicines Is Maintained at Buy by Needham
Ami Fadia Reiterates Buy on Revolution Medicines, Slightly Lowers Price Target to $183 Amid Higher Non‑Cash Expenses and Expanded RASolute 301 Trial
TIPRANKS  ·  05-07
Ami Fadia Reiterates Buy on Revolution Medicines, Slightly Lowers Price Target to $183 Amid Higher Non‑Cash Expenses and Expanded RASolute 301 Trial
Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD) and Sera Prognostics (SERA)
TIPRANKS  ·  05-07
Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD) and Sera Prognostics (SERA)
Revolution Medicines Inc reports results for the quarter ended March 31 - Earnings Summary
Reuters  ·  05-07
Revolution Medicines Inc reports results for the quarter ended March 31 - Earnings Summary
Promising Revolution Medicines pancreatic cancer drug has high rate of mostly manageable side effects
Reuters  ·  05-07
Promising Revolution Medicines pancreatic cancer drug has high rate of mostly manageable side effects
Earnings Flash (RVMD) Revolution Medicines Posts Q1 Per Share Loss $-2.29, vs. FactSet Est Loss of $-1.85
MT Newswires Live  ·  05-07
Earnings Flash (RVMD) Revolution Medicines Posts Q1 Per Share Loss $-2.29, vs. FactSet Est Loss of $-1.85
Revolution Medicines Q1 net loss widens to $453.8 million
Reuters  ·  05-07
Revolution Medicines Q1 net loss widens to $453.8 million
Revolution Medicines Q1 EPS $(2.29) Misses $(1.82) Estimate
Benzinga  ·  05-07
Revolution Medicines Q1 EPS $(2.29) Misses $(1.82) Estimate
BRIEF-Revolution Medicines Q1 EPS USD -2.29
Reuters  ·  05-07
BRIEF-Revolution Medicines Q1 EPS USD -2.29
Revolution Medicines Q1 Operating Expenses USD 445.222 Million
THOMSON REUTERS  ·  05-07
Revolution Medicines Q1 Operating Expenses USD 445.222 Million
Revolution Medicines Inc - Updates FY2026 Gaap Operating Expenses Guidance to $1.7-$1.8 Bln
THOMSON REUTERS  ·  05-07
Revolution Medicines Inc - Updates FY2026 Gaap Operating Expenses Guidance to $1.7-$1.8 Bln

Introduction

Company Name.
Revolution Medicines, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Revolution Medicines, Inc., a clinical-stage oncology company, developing novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) Inhibitors designed to suppress oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. The company's RAS(ON) Inhibitors RMC-6236 (RASMULTI), RMC-6291 (RASG12C), and RMC-9805 (RASG12D) are in clinical development. Its additional RAS(ON) Inhibitors in its pipeline include RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), which are in IND-enabling development, and additional compounds targeting other RAS variants. The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Issue price:
--